Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue BMJ Open Année : 2021

Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol

Damien Roux
David Schnell
Benoît Veber
  • Fonction : Auteur
Gaetan Beduneau
  • Fonction : Auteur
Mai-Anh Nay

Résumé

Introduction: Pre-emptive inhaled antibiotics may be effective to reduce the occurrence of ventilator-associated pneumonia among critically ill patients. Meta-analysis of small sample size trials showed a favourable signal. Inhaled antibiotics are associated with a reduced emergence of antibiotic resistant bacteria. The aim of this trial is to evaluate the benefit of a 3-day course of inhaled antibiotics among patients undergoing invasive mechanical ventilation for more than 3 days on the occurrence of ventilator-associated pneumonia. Methods and analysis: Academic, investigator-initiated, parallel two group arms, double-blind, multicentre superiority randomised controlled trial. Patients invasively ventilated more than 3 days will be randomised to receive 20 mg/kg inhaled amikacin daily for 3 days or inhaled placebo (0.9% Sodium Chloride). Occurrence of ventilator-associated pneumonia will be recorded based on a standardised diagnostic framework from randomisation to day 28 and adjudicated by a centralised blinded committee. Ethics and dissemination: The protocol and amendments have been approved by the regional ethics review board and French competent authorities (Comité de protection des personnes Ouest I, No.2016-R29). All patients will be included after informed consent according to French law. Results will be disseminated in international scientific journals. Trial registration numbers: EudraCT 2016-001054-17 and NCT03149640.
Fichier principal
Vignette du fichier
e048591.full.pdf (654.21 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03371249 , version 1 (08-10-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Elsa Tavernier, Francois Barbier, Ferhat Meziani, Jean-Pierre Quenot, Jean-Etienne Herbrecht, et al.. Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol. BMJ Open, 2021, 11 (9), 10 p. ⟨10.1136/bmjopen-2020-048591⟩. ⟨hal-03371249⟩
132 Consultations
43 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More